StockIQpro
NASDAQ:VRCA

Verrica Pharmaceuticals Inc.

Track all markets on TradingView
Track all markets on TradingView

Verrica Pharmaceuticals Inc.'s revenue grew 370.2% in fiscal 2025 to $35.6M while operating margin rose to −34.2%, its highest in 5 years. Free cash flow was −$17.6M, −49.5% of revenue, and the diluted share count rose 105.6%.Summary generated from Verrica Pharmaceuticals Inc.'s SEC filings. Latest annual report filed Mar 11, 2026.

Key statistics

Fiscal 2025 from SEC filings. Methodology
Revenue (FY25)$35.6M
Revenue growth+370.2%
Revenue, 5-yr CAGRn/a
Gross marginn/a
Operating margin−34.2%
Net margin−50.3%
ROICn/a
Return on equity−240.4%
Debt / equity0.00
Free cash flow−$17.6M
FCF margin−49.5%
Share count change+105.6%

Financials

Fiscal years, $M
Item20212022202320242025
Revenue1295836
Operating income−31−21−66−66−12
Net income−35−24−67−77−18
Free cash flow−28−19−39−61−18

Recent filings

From SEC EDGAR

Peers

Pharmaceutical preparations